• INCLUSION CRITERIA:

  1. Participant is from 6 to 18 years of age, inclusive;
  2. Participant has a diagnosis of non-infectious uveitis associated juvenile idiopathic arthritis (JIA) requiring treatment to control their intraocular inflammatory disease with anti-inflammatory medications, systemic and/or topical at high frequency intervals (greater than or equal to T.I.D.).
  3. Participant's uveitis is considered active on current regimen
  4. Participant has uveitis with at least a grade of 1+ for anterior chamber cells in at least one eye
  5. Participant's uveitis is currently treated or untreated at the time of enrollment
  6. Participant has visual acuity in at least one eye of 20/640 or better (ETDRS or EVA-ATS, logMAR less than 1.54).

  7. Participant has normal renal or liver function or evidence of no worse than mild abnormalities as defined by the "Common Toxicity Criteria for Adverse Events" (CTCAE) version 3.0, including:

     Test Parameter Age (yrs) Pediatric Mild Limit

     Serum creatinine 6-12 1.0 mg/dL

     13-18 1.6 mg/dL

     Proteinuria 6-18 3 g/L

     Uric acid 6-18 9.9 mg/dL

     BUN 6-18 2.0 upper normal limit

     AST (SGOT) 6-18 2.5 upper normal limit

     ALT (SGPT) 6-18 2.5 upper normal limit

  8. Participant agrees not to undergo elective ocular surgery (e.g., cataract extraction) for the first 6 months of the study.
  9. Participant has an absolute neutrophil count above 750.
  10. Participant is not currently pregnant or lactating.
  11. Participant with reproductive potential and who is sexually active agrees to use acceptable birth control methods throughout the course of the study and for 6 months after completion of treatment.
  12. All participants at enrollment has a parent or legal guardian who is able to understand and sign a consent form on their behalf before entering into the study, and participant signs an assent as a minor.
  13. Meet American College of Rheumatology Criteria for JRA/JIA (Appendix) but is not newly diagnosed, and has had systemic treatment for their uveitis.
  14. Be able to undergo slit lamp biomicroscopy for assessment of anterior chamber cells.
  15. Be able to comply with the study requirements.
  16. Be up to date on all recommended childhood immunizations.

EXCLUSION CRITERIA:

1. Participants under the age of 6 years will not be enrolled in the study due to the reported higher incidence of adverse events related or unrelated to the administration of daclizumab in post-transplant pediatric studies compared to children over age 6.
2. Participants who had received previous treatment with an IL-2 directed monoclonal antibody or any other investigational agent that would interfere with the ability to evaluate the safety, efficacy or pharmacokinetics of daclizumab.
3. Participants with a history or diagnosis of Behcet's disease.
4. Participant has a significant active infection.
5. Participant has a history of cancer (other than a non-melanoma skin cancer) diagnosed within the past 5 years.
6. Participant has used latanoprost (Xalatan) within two weeks prior to study enrollment or has a likely need.
7. Participant for whom administration of fluorescein dye is medically contraindicated.
8. Have a media opacity that precludes assessment of anterior chamber inflammation.
9. Be a female who is pregnant or lactating.
10. Refuse to use contraception during the study and 6 months after termination of active study therapy, if child-bearing or fathering potential exists.
11. Have active serious infections or a history of recurring serious infections.
12. Evidence of spondyloarthropathy or enthesopathy.
13. Have active joint or systemic inflammation requiring immediate addition or increase in systemic anti-inflammatory medications.